Smith & Nephew plc
Smith & Nephew plc (SN.L) Stock Competitors & Peer Comparison
See (SN.L) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SN.L | £1,156.50 | -0.52% | 10.1B | 33.04 | £0.35 | +2.76% |
| 0A0L.IL | £351.42 | -5.26% | 71.7B | 185.57 | £1.99 | +0.31% |
| 0GZV.IL | £188.75 | -3.74% | 53B | 24.50 | £7.92 | +2.43% |
| 0YAY.L | £299.20 | -0.60% | 20.1B | N/A | N/A | +0.78% |
| 0QPY.L | £337.10 | +0.09% | 13.9B | 32.57 | £10.35 | +1.98% |
| MGP.L | £212.00 | +0.47% | 268.1M | 35.33 | £0.06 | N/A |
| MXCT.L | £147.69 | -7.69% | 157M | -4.92 | -£0.30 | N/A |
| EKF.L | £31.00 | +0.00% | 139.2M | 31.00 | £0.01 | N/A |
| CREO.L | £12.50 | -5.66% | 51.6M | -1.56 | -£0.08 | N/A |
| IUG.L | £12.88 | +0.00% | 42.6M | -12.87 | -£0.01 | N/A |
Stock Comparison
SN.L vs 0A0L.IL Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, 0A0L.IL has a market cap of 71.7B. Regarding current trading prices, SN.L is priced at £1,156.50, while 0A0L.IL trades at £351.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas 0A0L.IL's P/E ratio is 185.57. In terms of profitability, SN.L's ROE is +0.05%, compared to 0A0L.IL's ROE of +0.36%. Regarding short-term risk, SN.L is less volatile compared to 0A0L.IL. This indicates potentially lower risk in terms of short-term price fluctuations for SN.L.Check 0A0L.IL's competition here
SN.L vs 0GZV.IL Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, 0GZV.IL has a market cap of 53B. Regarding current trading prices, SN.L is priced at £1,156.50, while 0GZV.IL trades at £188.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas 0GZV.IL's P/E ratio is 24.50. In terms of profitability, SN.L's ROE is +0.05%, compared to 0GZV.IL's ROE of +0.05%. Regarding short-term risk, SN.L is more volatile compared to 0GZV.IL. This indicates potentially higher risk in terms of short-term price fluctuations for SN.L.Check 0GZV.IL's competition here
SN.L vs 0YAY.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, 0YAY.L has a market cap of 20.1B. Regarding current trading prices, SN.L is priced at £1,156.50, while 0YAY.L trades at £299.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas 0YAY.L's P/E ratio is N/A. In terms of profitability, SN.L's ROE is +0.05%, compared to 0YAY.L's ROE of +0.04%. Regarding short-term risk, SN.L is more volatile compared to 0YAY.L. This indicates potentially higher risk in terms of short-term price fluctuations for SN.L.Check 0YAY.L's competition here
SN.L vs 0QPY.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, 0QPY.L has a market cap of 13.9B. Regarding current trading prices, SN.L is priced at £1,156.50, while 0QPY.L trades at £337.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas 0QPY.L's P/E ratio is 32.57. In terms of profitability, SN.L's ROE is +0.05%, compared to 0QPY.L's ROE of +0.23%. Regarding short-term risk, SN.L is more volatile compared to 0QPY.L. This indicates potentially higher risk in terms of short-term price fluctuations for SN.L.Check 0QPY.L's competition here
SN.L vs MGP.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, MGP.L has a market cap of 268.1M. Regarding current trading prices, SN.L is priced at £1,156.50, while MGP.L trades at £212.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas MGP.L's P/E ratio is 35.33. In terms of profitability, SN.L's ROE is +0.05%, compared to MGP.L's ROE of +0.12%. Regarding short-term risk, SN.L is more volatile compared to MGP.L. This indicates potentially higher risk in terms of short-term price fluctuations for SN.L.Check MGP.L's competition here
SN.L vs MXCT.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, MXCT.L has a market cap of 157M. Regarding current trading prices, SN.L is priced at £1,156.50, while MXCT.L trades at £147.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas MXCT.L's P/E ratio is -4.92. In terms of profitability, SN.L's ROE is +0.05%, compared to MXCT.L's ROE of -0.20%. Regarding short-term risk, SN.L is less volatile compared to MXCT.L. This indicates potentially lower risk in terms of short-term price fluctuations for SN.L.Check MXCT.L's competition here
SN.L vs EKF.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, EKF.L has a market cap of 139.2M. Regarding current trading prices, SN.L is priced at £1,156.50, while EKF.L trades at £31.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas EKF.L's P/E ratio is 31.00. In terms of profitability, SN.L's ROE is +0.05%, compared to EKF.L's ROE of +0.09%. Regarding short-term risk, SN.L is less volatile compared to EKF.L. This indicates potentially lower risk in terms of short-term price fluctuations for SN.L.Check EKF.L's competition here
SN.L vs CREO.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, CREO.L has a market cap of 51.6M. Regarding current trading prices, SN.L is priced at £1,156.50, while CREO.L trades at £12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas CREO.L's P/E ratio is -1.56. In terms of profitability, SN.L's ROE is +0.05%, compared to CREO.L's ROE of -0.50%. Regarding short-term risk, SN.L is less volatile compared to CREO.L. This indicates potentially lower risk in terms of short-term price fluctuations for SN.L.Check CREO.L's competition here
SN.L vs IUG.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, IUG.L has a market cap of 42.6M. Regarding current trading prices, SN.L is priced at £1,156.50, while IUG.L trades at £12.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas IUG.L's P/E ratio is -12.87. In terms of profitability, SN.L's ROE is +0.05%, compared to IUG.L's ROE of -0.38%. Regarding short-term risk, SN.L is more volatile compared to IUG.L. This indicates potentially higher risk in terms of short-term price fluctuations for SN.L.Check IUG.L's competition here
SN.L vs 0QMX.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, 0QMX.L has a market cap of 33.6M. Regarding current trading prices, SN.L is priced at £1,156.50, while 0QMX.L trades at £4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas 0QMX.L's P/E ratio is -4.25. In terms of profitability, SN.L's ROE is +0.05%, compared to 0QMX.L's ROE of -0.07%. Regarding short-term risk, SN.L is more volatile compared to 0QMX.L. This indicates potentially higher risk in terms of short-term price fluctuations for SN.L.Check 0QMX.L's competition here
SN.L vs NCYT.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, NCYT.L has a market cap of 27.9M. Regarding current trading prices, SN.L is priced at £1,156.50, while NCYT.L trades at £39.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas NCYT.L's P/E ratio is -0.72. In terms of profitability, SN.L's ROE is +0.05%, compared to NCYT.L's ROE of -0.70%. Regarding short-term risk, SN.L is less volatile compared to NCYT.L. This indicates potentially lower risk in terms of short-term price fluctuations for SN.L.Check NCYT.L's competition here
SN.L vs IHC.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, IHC.L has a market cap of 19.3M. Regarding current trading prices, SN.L is priced at £1,156.50, while IHC.L trades at £21.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas IHC.L's P/E ratio is -1.13. In terms of profitability, SN.L's ROE is +0.05%, compared to IHC.L's ROE of -0.67%. Regarding short-term risk, SN.L is less volatile compared to IHC.L. This indicates potentially lower risk in terms of short-term price fluctuations for SN.L.Check IHC.L's competition here
SN.L vs POLX.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, POLX.L has a market cap of 12.7M. Regarding current trading prices, SN.L is priced at £1,156.50, while POLX.L trades at £1.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas POLX.L's P/E ratio is -1.05. In terms of profitability, SN.L's ROE is +0.05%, compared to POLX.L's ROE of -0.48%. Regarding short-term risk, SN.L is less volatile compared to POLX.L. This indicates potentially lower risk in terms of short-term price fluctuations for SN.L.Check POLX.L's competition here
SN.L vs AVO.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, AVO.L has a market cap of 9.5M. Regarding current trading prices, SN.L is priced at £1,156.50, while AVO.L trades at £1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas AVO.L's P/E ratio is -0.25. In terms of profitability, SN.L's ROE is +0.05%, compared to AVO.L's ROE of +0.00%. Regarding short-term risk, SN.L is more volatile compared to AVO.L. This indicates potentially higher risk in terms of short-term price fluctuations for SN.L.Check AVO.L's competition here
SN.L vs RUA.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, RUA.L has a market cap of 7M. Regarding current trading prices, SN.L is priced at £1,156.50, while RUA.L trades at £11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas RUA.L's P/E ratio is 11.25. In terms of profitability, SN.L's ROE is +0.05%, compared to RUA.L's ROE of +0.03%. Regarding short-term risk, SN.L is less volatile compared to RUA.L. This indicates potentially lower risk in terms of short-term price fluctuations for SN.L.Check RUA.L's competition here
SN.L vs SUN.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, SUN.L has a market cap of 6.5M. Regarding current trading prices, SN.L is priced at £1,156.50, while SUN.L trades at £0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas SUN.L's P/E ratio is N/A. In terms of profitability, SN.L's ROE is +0.05%, compared to SUN.L's ROE of -0.21%. Regarding short-term risk, SN.L is more volatile compared to SUN.L. This indicates potentially higher risk in terms of short-term price fluctuations for SN.L.Check SUN.L's competition here
SN.L vs MHC.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, MHC.L has a market cap of 6.4M. Regarding current trading prices, SN.L is priced at £1,156.50, while MHC.L trades at £12.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas MHC.L's P/E ratio is -4.08. In terms of profitability, SN.L's ROE is +0.05%, compared to MHC.L's ROE of -0.25%. Regarding short-term risk, SN.L is less volatile compared to MHC.L. This indicates potentially lower risk in terms of short-term price fluctuations for SN.L.Check MHC.L's competition here
SN.L vs BELL.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, BELL.L has a market cap of 3M. Regarding current trading prices, SN.L is priced at £1,156.50, while BELL.L trades at £0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas BELL.L's P/E ratio is -0.07. In terms of profitability, SN.L's ROE is +0.05%, compared to BELL.L's ROE of -1.03%. Regarding short-term risk, SN.L is more volatile compared to BELL.L. This indicates potentially higher risk in terms of short-term price fluctuations for SN.L.Check BELL.L's competition here
SN.L vs DEMG.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, DEMG.L has a market cap of 663.6K. Regarding current trading prices, SN.L is priced at £1,156.50, while DEMG.L trades at £0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas DEMG.L's P/E ratio is N/A. In terms of profitability, SN.L's ROE is +0.05%, compared to DEMG.L's ROE of -0.42%. Regarding short-term risk, SN.L is less volatile compared to DEMG.L. This indicates potentially lower risk in terms of short-term price fluctuations for SN.L.Check DEMG.L's competition here
SN.L vs CIR.L Comparison August 2025
SN.L plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SN.L stands at 10.1B. In comparison, CIR.L has a market cap of 0. Regarding current trading prices, SN.L is priced at £1,156.50, while CIR.L trades at £34.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SN.L currently has a P/E ratio of 33.04, whereas CIR.L's P/E ratio is 34.00. In terms of profitability, SN.L's ROE is +0.05%, compared to CIR.L's ROE of +0.03%. Regarding short-term risk, SN.L is less volatile compared to CIR.L. This indicates potentially lower risk in terms of short-term price fluctuations for SN.L.Check CIR.L's competition here